# A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer

> **NCT00109239** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** rhuMAb VEGF (Bevacizumab)

## Key facts

- **NCT ID:** NCT00109239
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** —
- **Final completion:** 2002-09
- **Target enrollment:** — (—)
- **Last updated:** 2014-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00109239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00109239, "A Study of rhuMAb VEGF (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Treated Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00109239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*